EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis

Jinrun Chen, Yuqin Wu, Bofei Xu, Jiabei Hou, Yijing Li, Yuhan Hu, Yutuo Zhu, Wenqiao Zhang, Shuqi Feng, Huanting Jin, Yuchen Cheng, Yuanyuan Jin und 2 weitere

Advanced Science · 2026-04 · 13 (20)

DOI: 10.1002/advs.202519503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.02.2026. Verfasst von Jinrun Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Antigen-Presenting Cells, Pentacyclic Triterpenes, Uveitis, Autoimmune Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Wenzhou High-level Innovation Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of retina‐specific CD4 + T cells capable of breaking through the blood‐retinal barrier (BRB) was significantly associated with the onset and progression of autoimmune uveitis (AU). Antigen‐presenting cells (APCs) orchestrate this process by presenting retinal antigens to naïve CD4 + T cells and driving their differentiation into autoreactive CD4 + T cells. Here, we report an intestinal APCs‐targeted strategy for treating AU based on orally administered nanoCEL (diameter: 37.06 ± 0.12 nm), a pH‐responsive nanomedicine exhibiting a great gastric acid stability and a pH‐responsive drug release behavior. After oral administration, nanoCEL effectively penetrates the intestinal mucus barrier and targets APCs in the intestine. Using an experimental autoimmune uveitis rat model, oral administration of nanoCEL (2 mg/kg) exhibits a superior therapeutic efficacy than free CEL treatment by suppressing the antigen‐presenting ability of APCs and impairing pathogenic T cell differentiation. Additionally, nanoCEL medication protects the BRB from the damage of pathogenic T cells by the reduction of the infiltration of peripheral immune cells and the activation of retinal glial cells. Compared to free CEL, oral administration of nanoCEL remarkably enhances drug bioavailability and improves biosafety without apparent systemic toxicity. Thus, the proposed APC‐targeted nanodrug delivery system might be a promising strategy to treat AU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigen-Presenting CellsPentacyclic TriterpenesUveitisAutoimmune DiseasesNanomedicineRetinaAnimalsRatsAdministration, OralDisease Models, AnimalBlood-Retinal Barrier

Stichwörter der Autor:innen

APCs targetingautoimmune uveitiscelastrolnanomedicineoral administration

Substanzen

Pentacyclic Triterpenescelastrol

Autor:innen und Institutionen

  • National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
  • State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, and College of Life Sciences, Nankai University, Tianjin, China.

ORCID-Profile: Xingyi Li

Förderung

  • National Natural Science Foundation of China
  • Wenzhou High-level Innovation Team

Zitieren

APA

Chen, J., Wu, Y., Xu, B., Hou, J., Li, Y., Hu, Y., Zhu, Y., Zhang, W., Feng, S., Jin, H., Cheng, Y., Jin, Y., Zhou, J., & Li, X. (2026). Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis. Advanced Science, 13(20). https://doi.org/10.1002/advs.202519503

Vancouver

Chen J, Wu Y, Xu B, Hou J, Li Y, Hu Y, et al. Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis. Advanced Science. 2026;13(20). doi:10.1002/advs.202519503

BibTeX
@article{Chen2026,
  author = {Chen, Jinrun and Wu, Yuqin and Xu, Bofei and Hou, Jiabei and Li, Yijing and Hu, Yuhan and Zhu, Yutuo and Zhang, Wenqiao and Feng, Shuqi and Jin, Huanting and Cheng, Yuchen and Jin, Yuanyuan and Zhou, Jianhong and Li, Xingyi},
  title = {Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {20},
  doi = {10.1002/advs.202519503}
}
Kostenlos starten →